Alzheimer's drug patent given the go ahead
Pittsburgh-based pharmaceutical research and development firm Cognition Therapeutics (CogRx) announced April 1 that the company’s patent for numerous drug therapy candidates have been approved.
The molecular compounds in question are still investigational and not approved for clinical use but these drugs aim to halt the mechanisms of protein aggregates in the brain that are connected with onset of Alzheimer’s and other neurodegenerative diseases.
"The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease," said CogRx CEO Hank Safferstein in a statement.
CogRx has been developing screening technology that mirrors the chemical signatures of the central nervous system and pathogenesis of neurodegenerative disorders in order to test the effectiveness of potential drug treatments.
Filing for the U.S. National Stage Application number 13/263,162, known as "Inhibitors of Cognitive Decline," began in October of 2011.